Search research articles
Contact Us
Filters
Showing results (91-100 of 336) with videos related to
Page
of 34
Sort By:
The Breast Journal
|
May 12, 2001
Detection and Significance of Occult Axillary Metastatic Disease in Breast Cancer Patients
Kalliopi P. Siziopikou, Stuart J. Schnitt, James L. Connolly, et al.
Nature Reviews. Cancer
|
October 13, 2006
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants
Vered Stearns, Bryan Schneider, N Lynn Henry, et al.
The American Journal of Psychiatry
|
October 3, 2008
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression
N Lynn Henry, Vered Stearns, David A Flockhart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2013
CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer
James M Rae, Meredith Regan, Brian Leyland-Jones, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 10, 2009
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Michaela J Higgins, James M Rae, David A Flockhart, et al.
Breast Cancer Research : BCR
|
November 24, 2007
International Web-based consultation on priorities for translational breast cancer research
Mitch Dowsett, Aron Goldhirsch, Daniel F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2003
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583
Susan Halabi, Eric J Small, Daniel F Hayes, et al.
Journal of the National Cancer Institute
|
May 18, 2021
Response to Zhang and Yang
Torsten O Nielsen, Samuel C Y Leung, Lisa M McShane, et al.
The Breast Journal
|
March 11, 2004
Tamoxifen-induced radiation recall dermatitis
Eric A Singer, Robert D Warren, Marie F Pennanen, et al.
The Oncologist
|
December 10, 2013
Prediction of postchemotherapy ovarian function using markers of ovarian reserve
N Lynn Henry, Rong Xia, Anne F Schott, et al.
Page
of 34
Search research articles
Search
Showing results (91-100 of 336) with videos related to
Sort By:
Page
of 34
The Breast Journal
|
May 12, 2001
Detection and Significance of Occult Axillary Metastatic Disease in Breast Cancer Patients
Kalliopi P. Siziopikou, Stuart J. Schnitt, James L. Connolly, et al.
Nature Reviews. Cancer
|
October 13, 2006
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants
Vered Stearns, Bryan Schneider, N Lynn Henry, et al.
The American Journal of Psychiatry
|
October 3, 2008
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression
N Lynn Henry, Vered Stearns, David A Flockhart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2013
CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer
James M Rae, Meredith Regan, Brian Leyland-Jones, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 10, 2009
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Michaela J Higgins, James M Rae, David A Flockhart, et al.
Breast Cancer Research : BCR
|
November 24, 2007
International Web-based consultation on priorities for translational breast cancer research
Mitch Dowsett, Aron Goldhirsch, Daniel F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2003
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583
Susan Halabi, Eric J Small, Daniel F Hayes, et al.
Journal of the National Cancer Institute
|
May 18, 2021
Response to Zhang and Yang
Torsten O Nielsen, Samuel C Y Leung, Lisa M McShane, et al.
The Breast Journal
|
March 11, 2004
Tamoxifen-induced radiation recall dermatitis
Eric A Singer, Robert D Warren, Marie F Pennanen, et al.
The Oncologist
|
December 10, 2013
Prediction of postchemotherapy ovarian function using markers of ovarian reserve
N Lynn Henry, Rong Xia, Anne F Schott, et al.
Page
of 34